Drugs / AFM13-NK
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04074746 | Jul 2020 → Sep 2025 | B-cell non-Hodgkin lymphoma, anaplastic large cell lymphoma, classic Hodgkin lymphoma, mycosis fungoides +1 | M.D. Anderson Cancer Center | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AFM13-NK | “cord-blood-derived cytokine-preactivated and expanded NK cells precomplexed with AFM13 (AFM13-NK) in patients with CD30+ lymphoma refractory to BV and CPI.” PMID 40186077 ↗ Apr 2025 |
| Action | Deplete | “Giving AFM13 loaded with NK cells followed by AFM13 alone may kill more cancer cells” NCT04074746 ↗ |
| Modality | Cell therapy | “cord-blood-derived cytokine-preactivated and expanded NK cells” PMID 40186077 ↗ Apr 2025 |
| Route | Intravenous | “Given AFM13-NK cells IV” NCT04074746 ↗ |